

**SUMMARY STATEMENT**  
( Privileged Communication )

Release Date: 11/01/2010

PROGRAM CONTACT:  
Deirdre Joy

---

Application Number: 1 R21 AI094129-01

Principal Investigators (Listed Alphabetically):  
MYLER, PETER JOHN PHD (Contact)  
PARSONS, MARILYN PHD

Applicant Organization: SEATTLE BIOMEDICAL RESEARCH INSTITUTE

Review Group: PTHE  
Pathogenic Eukaryotes Study Section

Meeting Date: 10/14/2010  
Council: JAN 2011  
Requested Start: 04/01/2011

RFA/PA: PA10-069  
PCC: M93

---

Project Title: Ribosome profiling of Trypanosoma brucei

SRG Action: Impact/Priority Score: 10

Human Subjects: 10-No human subjects involved

Animal Subjects: 30-Vertebrate animals involved - no SRG concerns noted

Project Year	Direct Costs Requested	Estimated Cost
1		
2		
<hr/> TOTAL	<hr/>	<hr/>

---

**ADMINISTRATIVE BUDGET NOTE:** The budget shown is the requested budget and has not been adjusted to reflect any recommendations made by reviewers. If an award is planned, the costs will be calculated by Institute grants management staff based on the recommendations outlined below in the COMMITTEE BUDGET RECOMMENDATIONS section.

**Time has passed since the application was reviewed.** This sample may not reflect the latest format for summary statements. NIAID posts new samples periodically: <https://www.niaid.nih.gov/grants-contracts/sample-applications>

**The text from the application is copyrighted.** You may use it only for nonprofit educational purposes provided the document remains unchanged and the PI, the grantee organization, and NIAID are credited.

**Contact information.** If you have any questions, email the NIAID Office of Knowledge and Educational Resources at [deaweb@niaid.nih.gov](mailto:deaweb@niaid.nih.gov).

**1R21AI094129-01 MYLER, PETER**

**RESUME AND SUMMARY OF DISCUSSION:** This application seeks to use ribosome profiling technology to identify genes under translational control in the major developmental stages of *Trypanosoma brucei*, the causative agent of African trypanosomiasis. If successful, this work will have a huge impact in our understanding of transcription and post-transcription regulation in a medically important protozoan and provide an important resource for the community working on cell and molecular biology of trypanosomatids. Additional strengths are the track record of productivity of the investigator and co-investigator, which combines achievements in the field of molecular biology of kinetoplastid parasites and genomics, and the clever, cutting edge, and innovative approaches. Overall, this almost flawless and exciting application raises very high enthusiasm.

**DESCRIPTION (provided by applicant):** *Trypanosoma brucei*, the causative agent of African trypanosomiasis ("sleeping sickness"), causes more than 50,000 deaths annually. Related trypanosomatid pathogens, including *Trypanosoma cruzi* (the causative agent of Chagas' disease) and numerous *Leishmania* species (which cause a diverse spectrum of visceral, mucocutaneous, and cutaneous disease), cause even more morbidity and mortality worldwide. Each of these parasites undergoes a complex developmental cycle, alternating between mammalian and insect hosts, as well as proliferating and non-proliferating stages. Exactly how trypanosomatid gene expression gives rise to the different phenotypes at each stage is currently not well understood, but the relative contribution of gene-specific transcriptional control is low. Differences in post-transcriptional mRNA processing and stability undoubtedly play major roles but the poor correlation between mRNA and protein abundance during parasite development indicates that translational and/or post-translational controls are also important. This project seeks to globally and quantitatively assess the rate at which each mRNA is actively translated at any particular time by applying a recently-described technology that couples the ability to isolate the specific "footprints" of mRNAs that are occupied by ribosomes (an indicator of translation) with the depth and breadth of next generation sequencing. Aim 1 will establish the ribosome protection technology in *T. brucei*, using readily cultured non-pathogenic insect stage forms. It will optimize conditions for nuclease treatment to preserve mRNA fragments protected by ribosomes and for the generation of unbiased libraries from the RNA samples for next generation sequencing. It will also include maturation of the bioinformatics pipeline to analyze resulting sequence data. Aim 2 will expand into the pathogenic, mammalian stages of the parasite, and identify genes that are regulated at the level of translation during *T. brucei* development in infective as compared to non-infective forms. The proposed work will provide an important new tool for studying trypanosomatid gene expression, yielding a comprehensive view of the role of translational control in *T. brucei* and clues to its mechanisms, as well as new information on the extent of translation of individual gene products, such as potential drug targets. In addition, it should resolve the current debate over the function of the numerous recently identified RNAs that contain only short open-reading frames, and has the potential to identify non-canonical protein-coding open-reading frames, thus significantly enhancing the ongoing genome annotation.

**PROJECT NARRATIVE:** The parasite *Trypanosoma brucei* causes fatal human African trypanosomiasis (sleeping sickness) and drugs to treat the disease are toxic and facing resistance. Generating new drugs requires knowledge of which proteins are expressed in the disease-causing stages of parasite development. This project will apply a new technology to measure the initial steps of protein synthesis for all genes in the infective as compared to non-infective stages, thereby providing new information on candidate drug targets.

**CRITIQUE 1:**

Significance: 1  
Investigator(s): 1  
Innovation: 2

Approach: 2  
Environment: 1

**Overall Impact:** An excellent application by an established investigator with a long track record of productivity in both the trypanosome field and the field of genomics. The application is nicely written and aims at applying the recently published technique of ribosome profiling to the study of developmental gene control between different stages of *T. brucei*. The application of ribosome profiling coupled with next generation sequence would be (to my knowledge) a first on the trypanosome field. There is no doubt that the proposed research will finally reconcile the well established differences between the transcriptome and proteome of this organism, where it is now widely accepted that the bulk of the control of gene expression occurs at some step after transcription.

### 1. Significance:

#### Strengths

- The approach will no doubt reveal in a gene specific manner what genes are controlled postranscriptionally vs. those whose expression is controlled postranslationally (for which little is known in trypanosomes)

#### Weaknesses

- It is not clear how significant is to differentiate between stumpy and slender forms given the complications of separating the two forms (see below). This, however, is not a major weakness.

### 2. Investigator(s):

#### Strengths

- Very productive investigator well versed in the implementation of a wide array of genomic approaches for the study of trypanosomes
- Excellent collaboration with Dr. Parsons.

#### Weaknesses

- None.

### 3. Innovation:

#### Strengths

- The application of the ribosome profiling technique/deep sequencing is a first for the field.
- Clever and cutting edge.

#### Weaknesses

- No significant weaknesses

### 4. Approach:

#### Strengths

- Well developed rationale
- Excellent discussion of alternative approaches

#### Weaknesses

- The only weakness is the difficulty of obtaining sufficiently pure stumpy vs. slender forms. However, either way even the simple comparison of PCF to BSF is exciting enough.

## 5. Environment:

### Strengths

- Excellent

### Weaknesses

- None.

## Protections for Human Subjects:

Not Applicable (No Human Subjects)

## Vertebrate Animals:

Acceptable

## Biohazards:

Acceptable

## Resource Sharing Plans:

Acceptable

## Budget and Period of Support:

Recommend as Requested

## CRITIQUE 2:

Significance: 1

Investigator(s): 1

Innovation: 2

Approach: 1

Environment: 1

**Overall Impact:** The proposed work will examine the ribosome loading on mRNAs in the major developmental stages of the important parasite species *Trypanosoma brucei*. In addition to the medical importance of the system and related organisms, the molecular biology is highly unusual since post-transcriptional gene control is the “rule” in these organisms. The application is by an established pair of investigators with a very strong record of productivity, including in areas involving very large datasets (e.g., genome sequencing). The plan is very clearly written and involves a cutting edge approach that is perfectly suited to the task. A successful outcome will have a very high impact for many investigators in the future. A letter of support from the technique’s developer completes a near flawless application that is perfectly suited to the R21 funding mechanism.

## 1. Significance:

### **Strengths**

- African trypanosomes are important parasites in their own right as well as being representative of a class of organisms that includes many other pathogens
- Polycistronic transcription and post-transcriptional regulation occur in kinetoplastid organisms to a degree seen in no other system; hence they are perfect places to learn new things about how such control is affected, in general.
- The work will produce genome-wide data that will be of enormous interest to all investigators working on the cell and molecular biology of these parasites.

### **Weaknesses**

- None

## **2. Investigator(s):**

### **Strengths**

- Drs. Myler and Parsons have over 50 years experience between them working on the cell and molecular biology of kinetoplastid parasites, often in very productive collaboration
- They have individually been very productive and performed work at the cutting edge of the field.
- They have collaborated with each other on numerous projects with great success
- Myler has extensive experience leading large, genome-wide efforts (e.g., genome sequencing) that involve exactly the skills needed here, both in terms of personnel and information management (Dr. Myler directs the bioinformatic facility at his institution).
- The method to be used was developed by Dr. Ingolia who has already provided a detailed protocol to the investigators and provides an appropriate letter of support.

### **Weaknesses**

- None

## **3. Innovation:**

### **Strengths**

- This work represents the application of a cutting edge approach to a group of organisms that have not previously been the object of such global analyses.

### **Weaknesses**

- The method was not developed by the investigators and has already been used in other systems (e.g., yeast).

## **4. Approach:**

### **Strengths**

- The protocol is clearly described and follows an entirely logical plan
- Inclusion of the three major life stages will make for extremely interesting comparisons
- The potential to discover the role of some tantalizing, novel ORFs (that are extremely small and of unknown function) is well described
- Enough examples of transcripts that are strongly regulated post-transcriptionally already exist making validation of the data easy to do at an early stage in the experiments

- Excellent bioinformatic analysis

**Weaknesses**

- None

**5. Environment:**

**Strengths**

- Seattle BioMed has a long history of continuous productivity in the field
- The infrastructure necessary to do the work has been well established as a consequence of other genome-wide efforts carried out there
- There are few other places with the track record and resources to make a compelling case for successful execution of this cutting-edge project

**Weaknesses**

- None

**Protections for Human Subjects:**

Not Applicable (No Human Subjects)

**Vertebrate Animals:**

Acceptable

**Biohazards:**

Acceptable

**Resource Sharing Plans:**

Unacceptable

- The plans to share the data are incomplete in that it is not stated within what timeframe the data will be made publicly available. Please be specific.

**Budget and Period of Support:**

Recommend as Requested

**Additional Comments to Applicant (Optional):**

- A great use of R21 funds! A fantastic scenario would have the investigators comparing profiles from different places in the polysome profiles (e.g., from polysomes consisting of 1, 2, 3, etc. ribosomes) but I accept that this would be technically much more challenging and financially take the work outside the scope of a R21.

**CRITIQUE 3:**

Significance: 1

Investigator(s): 2

Innovation: 3  
Approach: 1  
Environment: 1

**Overall Impact:** This is a very strong application that seeks to define the mRNAs that are undergoing translation in *T. brucei*. The strengths are that the investigator and co-investigator are very versed in large scale genomic analysis, have chosen the correct strain ( 927) that is pleomorphic, have developed a cleaver way to derive both control and polysome associated mRNAs and will likely uncover a meaningful translational profile for protein synthesizing mRNA in trypanosomes. The weaknesses are that the group does not outline the controls they will use and the 'standard' mRNAs they expect to find. For example, can they use the leishmania data they note that they have already to detect highly regulate proteins that are regulated by efficient translation and not simply mRNA abundance? Thus, the major problem is that there needs to be some validation that the undertaken protocol is working. The group is very strong and the collaboration between Dr. Parsons and Myler will yield useful information.

**THE FOLLOWING RESUME SECTIONS WERE PREPARED BY THE SCIENTIFIC REVIEW OFFICER TO SUMMARIZE THE OUTCOME OF DISCUSSIONS OF THE REVIEW COMMITTEE ON THE FOLLOWING ISSUES:**

**VERTEBRATE ANIMAL (Resume): ACCEPTABLE**

**COMMITTEE BUDGET RECOMMENDATIONS: The budget was recommended as requested.**

---

NIH has modified its policy regarding the receipt of resubmissions (amended applications). See Guide Notice NOT-OD-10-080 at <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-10-080.html>.

The impact/priority score is calculated after discussion of an application by averaging the overall scores (1-9) given by all voting reviewers on the committee and multiplying by 10. The criterion scores are submitted prior to the meeting by the individual reviewers assigned to an application, and are not discussed specifically at the review meeting or calculated into the overall impact score. For details on the review process, see [http://grants.nih.gov/grants/peer\\_review\\_process.htm#scoring](http://grants.nih.gov/grants/peer_review_process.htm#scoring).

## MEETING ROSTER

### Pathogenic Eukaryotes Study Section Infectious Diseases and Microbiology Integrated Review Group CENTER FOR SCIENTIFIC REVIEW PTHE

October 14, 2010 - October 15, 2010

#### **CHAIRPERSON**

KLEIN, BRUCE STEVEN, MD  
PROFESSOR  
DEPARTMENT OF PEDIATRICS,  
MEDICAL MICROBIOLOGY AND IMMUNOLOGY  
UNIVERSITY OF WISCONSIN-MADISON  
MADISON, WI 53792

DEITSCH, KIRK W, PHD \*  
ASSOCIATE PROFESSOR  
DEPARTMENT OF MICROBIOLOGY  
AND IMMUNOLOGY  
WEILL MEDICAL COLLEGE  
CORNELL UNIVERSITY  
NEW YORK, NY 10021

#### **MEMBERS**

ALFONZO, JUAN D, PHD \*  
ASSOCIATE PROFESSOR  
DEPARTMENT OF MICROBIOLOGY  
OHIO STATE UNIVERSITY  
COLUMBUS, OH 43210

GOLDBERG, DANIEL E, PHD \*  
PROFESSOR  
DEPARTMENT OF MEDICINE  
SCHOOL OF MEDICINE  
HOWARD HUGHES MEDICAL INSTITUTE  
WASHINGTON UNIVERSITY  
ST. LOUIS, MO 63110

BELLOFATTO, VIVIAN , PHD \*  
PROFESSOR, VICE CHAIR FOR RESEARCH  
DEPARTMENT OF MICROBIOLOGY  
AND MOLECULAR GENETICS  
INTERNATIONAL CENTER FOR PUBLIC HEALTH  
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW  
JERSEY  
NEWARK, NJ 07101

GREENBERG, ROBERT M, PHD  
RESEARCH ASSOCIATE PROFESSOR  
DEPARTMENT OF PATHOBIOLOGY  
SCHOOL OF VETERINARY MEDICINE  
UNIVERSITY OF PENNSYLVANIA  
PHILADELPHIA, PA 19104

BOOTHROYD, JOHN C, PHD \*  
PROFESSOR  
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY  
SCHOOL OF MEDICINE  
STANFORD UNIVERSITY  
STANFORD, CA 94305

LORENZ, MICHAEL C, PHD \*  
ASSISTANT PROFESSOR  
DEPARTMENT OF MICROBIOLOGY  
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER  
HOUSTON, TX 77030

CORMACK, BRENDAN PATRICK, PHD  
ASSOCIATE PROFESSOR  
DEPARTMENT OF MOLECULAR BIOLOGY  
AND GENETICS  
SCHOOL OF MEDICINE  
JOHNS HOPKINS UNIVERSITY  
BALTIMORE, MD 21205

MORENO, SILVIA N, PHD  
PROFESSOR  
DEPARTMENT OF CELLULAR BIOLOGY  
CENTER FOR TROPICAL  
AND EMERGING GLOBAL DISEASES  
UNIVERSITY OF GEORGIA  
ATHENS, GA 30602

CUI, LIWANG , PHD  
PROFESSOR  
DEPARTMENT OF ENTOMOLOGY  
PENNSYLVANIA STATE UNIVERSITY  
UNIVERSITY PARK, PA 16802

MOYE-ROWLEY, W SCOTT, PHD \*  
PROFESSOR AND EXECUTIVE ASSOCIATE HEAD  
DEPARTMENT OF MOLECULAR PHYSIOLOGY  
AND BIOPHYSICS  
CARVER COLLEGE OF MEDICINE  
UNIVERSITY OF IOWA  
IOWA CITY, IA 52242

DEEPE, GEORGE S JR, MD  
PROFESSOR  
DIVISION OF INFECTIOUS DISEASES  
COLLEGE OF MEDICINE  
UNIVERSITY OF CINCINNATI  
CINCINNATI, OH 45267

NIERMAN, WILLIAM CHARLES, PHD  
PROFESSOR  
J.GRAIG VENTER INSTITUTE  
ROCKVILLE, MD 20850

NOVERR, MAIRI , PHD \*  
ASSOCIATE PROFESSOR  
DEPARTMENT OF MICROBIOLOGY,  
IMMUNOLOGY, AND PARASITOLOGY  
SCHOOL OF MEDICINE AT NEW ORLEANS  
LOUISIANA STATE UNIVERSITY  
NEW ORLEANS, LA 70119



PHILLIPS, MARGARET A, PHD  
PROFESSOR  
DEPARTMENT OF PHARMACOLOGY  
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL  
CENTER  
DALLAS, TX 75390

READ, LAURIE K, PHD  
PROFESSOR  
DEPARTMENT OF MICROBIOLOGY  
AND IMMUNOLOGY  
SCHOOL OF MEDICINE  
STATE UNIVERSITY OF NEW YORK AT BUFFALO  
BUFFALO, NY 14214

SAMUELSON, JOHN C, MD, PHD  
PROFESSOR  
DEPARTMENT OF MOLECULAR  
AND CELL BIOLOGY  
GOLDMAN SCHOOL OF DENTAL MEDICINE  
BOSTON UNIVERSITY  
BOSTON, MA 02118

SHA, WILLIAM C, PHD  
ASSOCIATE PROFESSOR  
DEPARTMENT OF MOLECULAR  
AND CELL BIOLOGY  
UNIVERSITY OF CALIFORNIA, BERKELEY  
BERKELEY, CA 94720

SHI, HAI NING, DVM, PHD  
ASSISTANT PROFESSOR  
HARVARD MEDICAL SCHOOL  
MUCOSAL IMMUNOLOGY LABORATORY  
MASSACHUSETTS GENERAL HOSPITAL  
CHARLESTOWN, MA 02129

SMITH, JOSEPH D, PHD  
ASSOCIATE MEMBER  
SEATTLE BIOMEDICAL RESEARCH INSTITUTE  
SEATTLE, WA 98109

TEMESVARI, LESLY A, PHD  
PROFESSOR  
DEPARTMENT OF BIOLOGICAL SCIENCES  
CLEMSON UNIVERSITY  
CLEMSON, SC 29634

ULLMAN, BUDDY , PHD \*  
PROFESSOR  
DEPARTMENT OF BIOCHEMISTRY AND  
MOLECULAR BIOLOGY  
OREGON HEALTH AND SCIENCE UNIVERSITY  
PORTLAND, OR 97201

WORMLEY, FLOYD L JR, PHD \*  
ASSISTANT PROFESSOR  
DEPARTMENT OF BIOLOGY  
UNIVERSITY OF TEXAS AT SAN ANTONIO  
SAN ANTONIO, TX 78249

ZAVALA, FIDEL P, MD  
PROFESSOR  
DEPARTMENT OF MOLECULAR MICROBIOLOGY  
AND IMMUNOLOGY  
BLOOMBERG SCHOOL OF PUBLIC HEALTH  
JOHNS HOPKINS UNIVERSITY  
BALTIMORE, MD 21205

### **MAIL REVIEWER(S)**

FRANCIS, MICHAEL M, PHD  
ASSISTANT PROFESSOR  
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL  
WORCESTER, MA 01605

LEE, CHAO-HUNG , PHD  
PROFESSOR  
DEPARTMENT OF PATHOLOGY  
AND LABORATORY MEDICINE  
SCHOOL OF MEDICINE  
INDIANA UNIVERSITY  
INDIANAPOLIS, IN 46202

LEWIS, WILLIAM , MD  
PROFESSOR  
DEPARTMENT OF PATHOLOGY  
AND LABORATORY MEDICINE  
SCHOOL OF MEDICINE  
EMORY UNIVERSITY  
ATLANTA, GA 30322

PAULSON, ROBERT FRANK, PHD  
ASSOCIATE PROFESSOR  
DEPARTMENT OF VETERINARY AND BIOMEDICAL  
SCIENCES  
CENTER FOR MOLECULAR IMMUNOLOGY AND  
INFECTIOUS DISEASE  
THE PENNSYLVANIA STATE UNIVERSITY  
UNIVERSITY PARK, PA 16802

SCHAFFER, WILLIAM R, PHD  
PROGRAM LEADER  
MRC LABORATORY OF MOLECULAR BIOLOGY  
DIVISION OF CELL BIOLOGY  
CAMBRIDGE, CB22QH  
UNITED KINGDOM

### **SCIENTIFIC REVIEW ADMINISTRATOR**

BOUNDS, TERA , DVM, PHD  
SCIENTIFIC REVIEW OFFICER  
CENTER FOR SCIENTIFIC REVIEW  
NATIONAL INSTITUTES OF HEALTH  
BETHESDA, MD 20892

### **GRANTS TECHNICAL ASSISTANT**

WASHINGTON, KELLIE L  
EXTRAMURAL SUPPORT ASSISTANT  
CENTER FOR SCIENTIFIC REVIEW  
NATIONAL INSTITUTES OF HEALTH  
BETHESDA, MD 20892

\* Temporary Member. For grant applications, temporary members may participate in the entire meeting or may review only selected applications as needed.

Consultants are required to absent themselves from the room during the review of any application if their presence would constitute or appear to constitute a conflict of interest.